MRIs, MRI-Guided Biopsies Detect Prostate Cancer Affordably MRIs, MRI-Guided Biopsies Detect Prostate Cancer Affordably
Standard biopsies sometimes fail to detect prostate cancer or produce false positives. MRI plus MRI-guided biopsies not only produce more accurate results but carry a fair price tag, researchers said.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 29, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
The little-known 'pain' that could be a hidden sign of prostate cancer
NHS doctor Dr Kishan Vithlani is now warning that early detection of prostate cancer is key (Source: Daily Express - Health)
Source: Daily Express - Health - November 28, 2023 Category: Consumer Health News Source Type: news
Diagnostic Imaging Not Yet Enough for Biopsy-Free Radical Prostatectomy
(MedPage Today) -- While prostate-specific membrane antigen (PSMA)-PET may improve diagnostic accuracy in suspected prostate cancer, it may not be accurate enough to skip the biopsy when considering radical prostatectomy.
In a retrospective review... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 27, 2023 Category: Hematology Source Type: news
F-18 fluciclovine PET/CT detects metastatic breast cancer
In this study, Mushtaq and colleagues enrolled 20 women with new or suspected recurrent ILC from a previous trial at Emory University. Patients had undergone PET/CT scans after IV administration of F-18 fluciclovine and Ga-68 PSMA on separate days. For comparison, conventional imaging included CT or bone scans in 13 patients and F-18 FDG-PET in seven patients.An image from Mushtaq's presentation showing a comparison between PET radiotracers in a patient with ILC. Image courtesy of Aliza Mushtaq, MD, Emory University.Three experts assessed radiotracer uptake per patient as well as in three regions per patient: ipsilateral a...
Source: AuntMinnie.com Headlines - November 27, 2023 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Breast Imaging 2023 Source Type: news
Propella Therapeutics, Pittsboro firm with 5 employees, sold for $175M
As part of the acquisition, Astellas will acquire Propella's lead asset, a potential treatment for metastatic prostate cancer. Astellas, which opened a $100 million plant in North Carolina in 2022, has run afoul of both U.S. and British authorities in recent years. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 27, 2023 Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news
PET tracer shows promise in prostate cancer patients
CHICAGO – Gallium-68 (Ga-68) RM2-PET/MRI is better than MRI alone for detecting relapse in prostate cancer patients, according to research presented November 26 at RSNA 2023.
Moreover, the approach could help detect disease that other effective prostate cancer PET radiotracers may miss, said Heying Duan, MD, a nuclear medicine research scientist at Stanford University, during a November 26 scientific session.
“You've hear a lot about PSMA. I wanted to introduce a new player in the game: gallium-68 GRPR antagonist,” Duan told attendees, during a scientific session on prostate cancer imaging.
Several prostate-specif...
Source: AuntMinnie.com Headlines - November 26, 2023 Category: Radiology Authors: Will Morton Tags: Subspecialties Resources Genitourinary Radiology Nuclear Radiology Conference RSNA 2023 Source Type: news
GP shares three symptoms of prostate cancer 'common in older men'
Prostate cancer can affect men at any age but is usually seen in older age groups. (Source: Daily Express - Health)
Source: Daily Express - Health - November 25, 2023 Category: Consumer Health News Source Type: news
Four red flag symptoms of prostate cancer every man should look out for when they pee
These symptoms are considered red flags for prostate disease, which although more likely to be due to benign disease, could signify prostate cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - November 21, 2023 Category: Consumer Health News Source Type: news
New targeted cancer treatment now offered at Upstate
Known as radioligand therapy, it is used to treat neuroendocrine tumors and prostate cancers. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - November 21, 2023 Category: Universities & Medical Training Tags: News Source Type: news
Episode 6: Transgender Patients and Prostate Cancer Episode 6: Transgender Patients and Prostate Cancer
Drs Sandhya Srinivas and Aria F. Olumi discuss barriers to prostate cancer screening, diagnosis and treatment for transgender patients, and ways to provide gender-affirming, wraparound care.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 21, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Pfizer and Astellas & #039; XTANDI ® approved by U.S. FDA in earlier prostate cancer treatment setting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced that the companies received an approval by the U.S. Food and Drug Administration (FDA) of a supplemental New Drug Application for XTANDI® (enzalutamide), following FDA expedited development and review programs (Priority Review designation, Fast Track designation, Real-time Oncology Review), based on results from the Phase 3 EMBARK trial. (Source: World Pharma News)
Source: World Pharma News - November 21, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
GP practices to recruit men for prostate cancer screening trial next year
A new prostate cancer screening trial is set to begin next year, which will recruit men at higher risk via their GP practice. (Source: GP Online News)
Source: GP Online News - November 20, 2023 Category: Primary Care Tags: Clinical News Source Type: news
FDA Expands Enzalutamide Approval to Earlier Prostate Cancer FDA Expands Enzalutamide Approval to Earlier Prostate Cancer
The expanded approval makes enzalutamide the first and only approved androgen receptor signaling inhibitor in the nonmetastatic castration-sensitive prostate cancer setting.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 17, 2023 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Alert Source Type: news
Shine reaches supply agreement with Nucleus RadioPharma
Lutetium-177 (Lu-177) producer Shine Technologies has reached a long-term supply agreement with Nucleus RadioPharma, a development, manufacturing, and supply chain organization for radiopharmaceuticals. Under the multiyear agreement, Shine will provide Lu-177 to Nucleus RadioPharma's radioligand therapy offerings for targeted radiopharmaceutical treatments for neuroendocrine tumors and prostate cancer. The partnership also ensures Nucleus will be supplied with the radioisotope required for their therapies in clinical trials as they investigate the efficacy of targeted radiopharmaceuticals in additional cancer types.Shin...
Source: AuntMinnie.com Headlines - November 17, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Pfizer and Astellas' Xtandi Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
TOKYO and NEW YORK, Nov. 16, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, " Astellas " ) and Pfizer Inc. (NYSE: PFE) today announced that the companies received an approval by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2023 Category: Drugs & Pharmacology Source Type: news
